Skip to main content
Top
Published in: Abdominal Radiology 10/2023

30-07-2023 | Ascites | Pancreas

Evaluation of the performance of and interobserver agreement on postoperative baseline CT findings in the identification of locoregional recurrence in patients with pancreatic ductal adenocarcinoma

Authors: Hüseyin Akkaya, Selim Özdemir, Okan Dilek, Ali Can Topaloglu, Ahmet Ziya Bayhan, Zeynel Abidin Taş, Cihan Gökler, Bozkurt Gülek

Published in: Abdominal Radiology | Issue 10/2023

Login to get access

Abstract

Purpose

To evaluate interobserver agreement on the findings of baseline contrast-enhanced multidetector computed tomography (CE-MDCT) performed at the postoperative third month in patients who underwent surgery due to ductal adenocarcinoma of the pancreatic head and investigate the value of these findings in predicting locoregional recurrence.

Material and methods

The baseline CE-MDCT images of 198 patients who underwent the Whipple procedure due to pancreatic head tumors were evaluated independently by three radiologists at the postoperative third month. The radiologists were asked to note suspicious findings in terms of locoregional recurrence, including postoperative fat stranding, the presence of perivascular contrast-enhanced solid tissue, short diameter of solid tissue if present, the shape of solid tissue (convex/concave), presence of peritoneal implants, diameter (mm) of pancreatic duct dilatation if present, the presence of lymph nodes larger than 5 mm, portal vein stenosis (≥50 and <50%), the presence of ascites, and the presence of distant metastases, as specified by the Society of Abdominal Radiology in October 2022. The agreement between the radiologists and the value of these parameters in predicting locoregional recurrence were investigated.

Results

Among the CE-MDCT findings evaluated, the radiologists had a moderate-to-high level of agreement concerning the presence of perivascular contrast-enhanced solid tissue. However, there was a poor interobserver agreement on the shape of solid tissue. A very high level of agreement was found among the radiologists in the evaluation of pancreatic duct dilatation, peritoneal implants, ascites, and the presence of distant metastases. According to the univariate analysis, the rates of portal vein stenosis had a 1.419 -fold effect [odds ratio (OR)=1.419, [95% confidence interval (CI)= 0.548–3.679, p=0.041], lymph node presence had a 2.337 -fold effect [odds ratio (OR)=2.337, [95% confidence interval (CI)= 1.165–4.686, p=0.015], perivascular contrast-enhanced solid tissue had 2.241 -fold effect [odds ratio (OR)=2.241, [95% confidence interval (CI)= 1.072–4.684, p=0.005]. In the multivariate analysis, perivascular contrast-enhanced solid tissue had 2.241 -fold effect [odds ratio (OR)=2.519, [95% confidence interval (CI)= 1.132–5.605, p=0.024].

Conclusion

In the postoperative baseline CE-MDCT examination, the presence of solid tissue, lymph node presence, and portal vein stenosis in the surgical bed are among the findings that may indicate early locoregional recurrence in patients with pancreatic ductal adenocarcinoma.

Graphical abstract

Literature
1.
go back to reference Chu LC, Wang ZJ, Kambadakone A, Hecht EM, He J, Narang AK et al. (2022) Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC. Abdom Radiol (NY) 48: 318. Epub ahead of print PMID: 36241752. Chu LC, Wang ZJ, Kambadakone A, Hecht EM, He J, Narang AK et al. (2022) Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC. Abdom Radiol (NY) 48: 318. Epub ahead of print PMID: 36241752.
2.
go back to reference Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, et al (2019) Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdominal radiology 44 (2):586-592CrossRefPubMed Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, et al (2019) Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdominal radiology 44 (2):586-592CrossRefPubMed
3.
go back to reference Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPWet al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and metaanalysis. European journal of radiology.2018;106:128-136.CrossRefPubMed Daamen LA, Groot VP, Goense L, Wessels FJ, Borel Rinkes IH, Intven MPWet al. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and metaanalysis. European journal of radiology.2018;106:128-136.CrossRefPubMed
4.
go back to reference Kulkarni NM, Mannelli L, Zins M, Bhosale PR, Arif-Tiwari H, Brook OR et al . White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. Abdom Radiol (NY). 2020;45(3):729-742.CrossRefPubMed Kulkarni NM, Mannelli L, Zins M, Bhosale PR, Arif-Tiwari H, Brook OR et al . White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals. Abdom Radiol (NY). 2020;45(3):729-742.CrossRefPubMed
6.
go back to reference Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022;8(11):1571-1578. Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022;8(11):1571-1578.
7.
go back to reference Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Eur J Cancer. 2021 ;151:3-13.CrossRefPubMed Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Eur J Cancer. 2021 ;151:3-13.CrossRefPubMed
8.
go back to reference Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg.2019;154:1038-1048.CrossRefPubMedPubMedCentral Jones RP, Psarelli EE, Jackson R, Ghaneh P, Halloran CM, Palmer DH. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg.2019;154:1038-1048.CrossRefPubMedPubMedCentral
9.
10.
go back to reference Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.2019;45:1674-1683.CrossRefPubMed Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.2019;45:1674-1683.CrossRefPubMed
11.
go back to reference Honselmann KC, Pergolini I, Castillo CF, Deshpande V, Ting D, Taylor MS. Tim- ing But Not Patterns of Recurrence Is Diferent Between Node negative and Node-positive Resected Pancreatic Cancer. Annals of surgery.2020;272:357-365.CrossRefPubMed Honselmann KC, Pergolini I, Castillo CF, Deshpande V, Ting D, Taylor MS. Tim- ing But Not Patterns of Recurrence Is Diferent Between Node negative and Node-positive Resected Pancreatic Cancer. Annals of surgery.2020;272:357-365.CrossRefPubMed
12.
go back to reference Ratnayake B, Savastyuk AY, Nayar M, Wilson CH, Windsor JA, Roberts K et al. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. J Clin Med. 2020 ;97:2132.CrossRef Ratnayake B, Savastyuk AY, Nayar M, Wilson CH, Windsor JA, Roberts K et al. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. J Clin Med. 2020 ;97:2132.CrossRef
13.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.CrossRefPubMed
14.
go back to reference Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS et al. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg. 2021;274:162-169.CrossRefPubMed Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS et al. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg. 2021;274:162-169.CrossRefPubMed
15.
go back to reference Wang ZJ, Arif-Tiwari H, Zaheer A, Ameli S, Bhosale PR, Do RK et al. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and func- tional imaging techniques. Abdominal radiology 2020;45:4273-4289.CrossRefPubMed Wang ZJ, Arif-Tiwari H, Zaheer A, Ameli S, Bhosale PR, Do RK et al. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and func- tional imaging techniques. Abdominal radiology 2020;45:4273-4289.CrossRefPubMed
16.
go back to reference Kovač JD, Mayer P, Hackert T, Klauss M. The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible? Acad Radiol. 2019;26:775-781.CrossRefPubMed Kovač JD, Mayer P, Hackert T, Klauss M. The Time to and Type of Pancreatic Cancer Recurrence after Surgical Resection: Is Prediction Possible? Acad Radiol. 2019;26:775-781.CrossRefPubMed
17.
go back to reference Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of surgery 2018;267:936-945.CrossRefPubMed Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of surgery 2018;267:936-945.CrossRefPubMed
18.
go back to reference Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery.2021;169:649-654.CrossRefPubMed Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery.2021;169:649-654.CrossRefPubMed
19.
go back to reference Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB et al.Pancreatic Adenocarcinoma, Version 2.NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.2021;19:439–457.CrossRefPubMed Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB et al.Pancreatic Adenocarcinoma, Version 2.NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.2021;19:439–457.CrossRefPubMed
20.
go back to reference Javed AA, Bleich K, Bagante F, He J, Weiss MJ, Wolfgang CL. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging fndings. Abdominal radiology.2018;43:1193-1203.CrossRefPubMed Javed AA, Bleich K, Bagante F, He J, Weiss MJ, Wolfgang CL. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging fndings. Abdominal radiology.2018;43:1193-1203.CrossRefPubMed
21.
go back to reference Kawai M, Hirono S, Okada KI, Miyazawa M, Kitahata Y, Kob- ayashi R. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer. Annals of surgical oncology.2021;28:1521-1532.CrossRefPubMed Kawai M, Hirono S, Okada KI, Miyazawa M, Kitahata Y, Kob- ayashi R. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer. Annals of surgical oncology.2021;28:1521-1532.CrossRefPubMed
22.
go back to reference Luchini C, Pea A, Yu J, He J, Salvia R, Riva G, Weiss MJ, Bassi C, Cameron JL, Hruban RH, Goggins M, Wolfgang CL, Scarpa A, Wood LD, Lawlor RT. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Mod Pathol. 2019;32(5):659-665.CrossRefPubMed Luchini C, Pea A, Yu J, He J, Salvia R, Riva G, Weiss MJ, Bassi C, Cameron JL, Hruban RH, Goggins M, Wolfgang CL, Scarpa A, Wood LD, Lawlor RT. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Mod Pathol. 2019;32(5):659-665.CrossRefPubMed
23.
go back to reference Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolf R et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not refected by radiographic indicators. Cancer 2012;118(23):5749- 5756.CrossRefPubMed Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolf R et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not refected by radiographic indicators. Cancer 2012;118(23):5749- 5756.CrossRefPubMed
24.
go back to reference Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology 2018;287(2):374-390.CrossRefPubMed Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology 2018;287(2):374-390.CrossRefPubMed
25.
go back to reference Quiney B, Harris A, McLaughlin P, Nicolaou S. Dual-energy CT increases reader confdence in the detection and diagnosis of hypoattenuating pancreatic lesions. Abdom Imaging 2015;40(4):859-864.CrossRefPubMed Quiney B, Harris A, McLaughlin P, Nicolaou S. Dual-energy CT increases reader confdence in the detection and diagnosis of hypoattenuating pancreatic lesions. Abdom Imaging 2015;40(4):859-864.CrossRefPubMed
26.
go back to reference Mileto A, Mazziotti S, Gaeta M, Bottari A, Zimbaro F, Giardina C. Pancreatic dual-source dual-energy CT: is it time to discard unenhanced imaging? Clin Radiol 2012;67(4):334-339.CrossRefPubMed Mileto A, Mazziotti S, Gaeta M, Bottari A, Zimbaro F, Giardina C. Pancreatic dual-source dual-energy CT: is it time to discard unenhanced imaging? Clin Radiol 2012;67(4):334-339.CrossRefPubMed
27.
go back to reference Han MY, Borazanci EH. Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies. Front Oncol. 2023;13:1138759.CrossRefPubMedPubMedCentral Han MY, Borazanci EH. Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies. Front Oncol. 2023;13:1138759.CrossRefPubMedPubMedCentral
28.
go back to reference Wang, Justin Dejia, and Andrew Eugene Hendifar. "Pancreatic cancer associated ascites: Risk factors, outcomes, and management." (2023): e16305-e16305.CrossRef Wang, Justin Dejia, and Andrew Eugene Hendifar. "Pancreatic cancer associated ascites: Risk factors, outcomes, and management." (2023): e16305-e16305.CrossRef
29.
go back to reference You MS, Lee SH, Choi YH, Shin BS, Paik WH, Ryu JK et al. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. BMC Cancer 2019; 19: 952.CrossRefPubMedPubMedCentral You MS, Lee SH, Choi YH, Shin BS, Paik WH, Ryu JK et al. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. BMC Cancer 2019; 19: 952.CrossRefPubMedPubMedCentral
30.
go back to reference Hur C, Tramontano AC, Dowling EC, Brooks GA, Jeon A, Brugge WR, et al. Early pancreatic ductal adenocarcinoma survival is dependent on size: positive implications for future targeted screening. Pancreas 2016; 45:1062–1066.CrossRefPubMedPubMedCentral Hur C, Tramontano AC, Dowling EC, Brooks GA, Jeon A, Brugge WR, et al. Early pancreatic ductal adenocarcinoma survival is dependent on size: positive implications for future targeted screening. Pancreas 2016; 45:1062–1066.CrossRefPubMedPubMedCentral
31.
go back to reference Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature. World J Gastroenterol. 2017;23:6420-6428.CrossRefPubMedPubMedCentral Lovecek M, Skalicky P, Chudacek J, Szkorupa M, Svebisova H, Lemstrova R et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature. World J Gastroenterol. 2017;23:6420-6428.CrossRefPubMedPubMedCentral
32.
go back to reference Lyu SC, Wang HX, Liu ZP, Wang J, Huang JC, He Q et al. Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages. World J Gastrointest Surg. 2022;14:1204-1218.CrossRefPubMedPubMedCentral Lyu SC, Wang HX, Liu ZP, Wang J, Huang JC, He Q et al. Clinical value of extended lymphadenectomy in radical surgery for pancreatic head carcinoma at different T stages. World J Gastrointest Surg. 2022;14:1204-1218.CrossRefPubMedPubMedCentral
33.
go back to reference Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50(12):1257e71.CrossRefPubMed Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50(12):1257e71.CrossRefPubMed
34.
go back to reference Kim HS, Kim YJ, Kim KG, Park JS. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Sci Rep 2019; 9: 17389.CrossRefPubMedPubMedCentral Kim HS, Kim YJ, Kim KG, Park JS. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Sci Rep 2019; 9: 17389.CrossRefPubMedPubMedCentral
35.
go back to reference Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB (Oxford). 2017 ;19(2):83-92.CrossRefPubMed Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB (Oxford). 2017 ;19(2):83-92.CrossRefPubMed
36.
go back to reference Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM et al. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Radiology 2018; 289: 710-718.CrossRefPubMed Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM et al. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. Radiology 2018; 289: 710-718.CrossRefPubMed
37.
go back to reference Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol 2018;25:3483e91.CrossRefPubMed Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol 2018;25:3483e91.CrossRefPubMed
Metadata
Title
Evaluation of the performance of and interobserver agreement on postoperative baseline CT findings in the identification of locoregional recurrence in patients with pancreatic ductal adenocarcinoma
Authors
Hüseyin Akkaya
Selim Özdemir
Okan Dilek
Ali Can Topaloglu
Ahmet Ziya Bayhan
Zeynel Abidin Taş
Cihan Gökler
Bozkurt Gülek
Publication date
30-07-2023
Publisher
Springer US
Keyword
Ascites
Published in
Abdominal Radiology / Issue 10/2023
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-04012-x

Other articles of this Issue 10/2023

Abdominal Radiology 10/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.